Scott Gottlieb, AP Images

Scott Got­tlieb is once again join­ing a team that en­joyed good times at the FDA un­der his high-en­er­gy stint at the helm

Right af­ter jump­ing on Michael Milken’s Faster­Cures board on Mon­day, the new­ly de­part­ed FDA com­mis­sion­er is back to­day with news about an­oth­er life sci­ences board post that gives him a ring­side chair to cheer on a lead play­er in the re­al-world ev­i­dence move­ment — one with very close ties to the FDA.

Ae­tion is re­port­ing this morn­ing that Got­tlieb is join­ing their board, a group that in­cludes Mo­hamad Makhzou­mi, a gen­er­al part­ner at New En­ter­prise As­so­ciates, where Got­tlieb re­turned af­ter step­ping out of his role at the FDA 2 years af­ter he start­ed.

Got­tlieb — one of the best con­nect­ed ex­ecs in bio­phar­ma — knows this com­pa­ny well. As head of FDA he cham­pi­oned the use of re­al-world ev­i­dence to help guide drug de­vel­op­ers and the agency in gain­ing greater ef­fi­cien­cies, which helped set up Ae­tion as a high-pro­file play­er in the game.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.